The state of Illinois currently has 463 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Chicago, Peoria, Springfield and Urbana.
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
NCT04423211
Recruiting
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen [PSA] after surgical removal of the pros... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: Alton Memorial Hospital, Alton, Illinois +43 locations
Conditions: Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Register for Updates
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
NCT04588545
Recruiting
The purpose of this study is to find out if radiation therapy followed by intrathecal trastuzumab and pertuzumab is safe and will result in improved survival in HER2 positive breast cancer which has metastasized to the leptomeninges.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: Northwestern University, Evanston, Illinois
Conditions: HER2-positive Breast Cancer, Leptomeningeal Metastasis, Leptomeningeal Disease
Register for Updates
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
NCT05863351
Recruiting
This phase III trial compares the effect of stero-ablative radiotherapy (SAbR) followed by standard of care systemic therapy, to standard of care systemic therapy alone, in patients with kidney cancer that has spread from where it first started (primary site) to a limited (2-5) number of places in the body (metastatic). Study doctors want to find out if this approach is better or worse than the usual approach for metastatic kidney cancer. The usual approach is defined as the care most people get... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: Saint Joseph Medical Center, Bloomington, Illinois +32 locations
Conditions: Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Register for Updates
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT04095364
Recruiting
This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of estrogen made by the body which in turn may stop the growth of tumor cells that need estrogen to grow. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: Saint Anthony's Health, Alton, Illinois +63 locations
Conditions: Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Ovarian Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Low Grade Fallopian Tube Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Ovarian Low Grade Serous Adenocarcinoma
Register for Updates
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
NCT05153239
Recruiting
Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of lurbinectedin as single agent (Group A) or the combination of lurbinectedin with irinotecan (Group B) versus Investigator's Choice (topotecan or irinotecan) as control arm (Group C), in Small-cell Lung Cancer (SCLC) patients who failed one prior platinum-containing line.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: Duly Health and Care, Joliet, Illinois
Conditions: Relapsed Small Cell Lung Cancer
Register for Updates
Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE Trial
NCT06216574
Recruiting
The goal of this clinical trial is to develop an effective internet-delivered program to help breast cancer survivors manage cancer-related sexual concerns. This study is being done to find out if the study approach is better or worse than the usual approach to helping breast cancer survivors manage cancer-related sexual concerns. The usual approach is defined as care most cancer survivors get for their cancer-related sexual concerns. Participants will complete a questionnaire and if they qual... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: Rush-Copley Medical Center, Aurora, Illinois +25 locations
Conditions: Breast Cancer Female
Register for Updates
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
NCT05502237
Recruiting
The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on progression-free survival (PFS) and overall survival (OS) in patients with untreated metastatic non-small cell lung cancer with no actionable genomic alteration.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: Illinois Cancer Care, Peoria, Illinois
Conditions: Non-small Cell Lung Cancer
Register for Updates
Social Interventions for Support During Treatment for Endometrial Cancer and Recurrence
NCT04930159
Recruiting
The SISTER study is a randomized trial, looking at various modalities of social support for Black patients undergoing treatment for endometrial cancer. There are three study arms: group support, 1:1 peer support, and enhanced usual care. The primary outcome is treatment completion, and the secondary outcome is social isolation.
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: The University of Chicago, Chicago, Illinois
Conditions: Endometrial Cancer
Register for Updates
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer
NCT03998202
Recruiting
This study will examine the association between low muscle mass (myopenia) at diagnosis and chemotherapy toxicity in older adults with newly diagnosed advanced colorectal cancer.
Gender:
All
Ages:
60 years and above
Trial Updated:
04/30/2024
Locations: OSF Saint Anthony's Health Center, Alton, Illinois +32 locations
Conditions: Colorectal Cancer, Sarcopenia
Register for Updates
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
NCT02366819
Recruiting
This pilot clinical trial studies genetic analysis-guided irontecan hydrochloride dosing of modified fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin (mFOLFIRINOX) in treating patients with gastroesophageal or stomach cancer that has spread from where it started to nearby tissue or lymph nodes. Drugs used in chemotherapy, such as fluorouracil, irinotecan hydrochloride, leucovorin calcium, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: University of Chicago Comprehensive Cancer Center, Chicago, Illinois +2 locations
Conditions: Esophageal Adenocarcinoma, Gastric Adenocarcinoma, Stage IIB Gastric Cancer, Stage IIIA Esophageal Adenocarcinoma, Stage IIIA Gastric Cancer, Stage IIIB Esophageal Adenocarcinoma, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Adenocarcinoma, Stage IIIC Gastric Cancer
Register for Updates
A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
NCT05200442
Recruiting
Doctors leading this study hope to learn about the safety of combining the study drug VS-6766 with another drug called cetuximab in colorectal cancer. This study is for individuals who have advanced colorectal cancer and their cancer has progressed while getting previous treatment or individuals who cannot take/tolerate previous treatments. If you choose to participate, your time in this research will last up to 24 months.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic, Advanced Colorectal Carcinoma, Advanced Colorectal Adenocarcinoma
Register for Updates
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
NCT05797831
Recruiting
This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy. The study will be conducted in 2 parts. Part 1 will evaluate safety and efficacy of two different doses of navtemadlin alongside an observational control arm to determine the Phase 3 navtemadlin dose. Part 2 will evaluate the efficacy and safety of navtemadlin Phase 3 dose compared to placebo.
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: Dr. Sudarshan K. Sharma, Ltd., Hinsdale, Illinois
Conditions: Endometrial Cancer
Register for Updates